These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11220554)

  • 1. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
    Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
    Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract]   [Full Text] [Related]  

  • 4. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
    Sekino N; Kashiwabara A; Inoue T; Kawasaki T; Ogata N; Sawashige K; Yamanouchi T
    Diabetes Obes Metab; 2003 May; 5(3):145-9. PubMed ID: 12681020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
    Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
    Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of troglitazone on lipoprotein(a) levels in obese subjects.
    Tack CJ; Smits P; DeMacker PN; Stalenhoef AF
    Diabetes Care; 1999 Oct; 22(10):1752-3. PubMed ID: 10526754
    [No Abstract]   [Full Text] [Related]  

  • 9. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
    Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A treatment for Mr WP: thiazolidinediones after troglitazone.
    Montague CT
    Diabet Med; 2002; 19 Suppl 1():7-9. PubMed ID: 11871423
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of troglitazone in type 2 diabetes mellitus.
    Gorson DM
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
    [No Abstract]   [Full Text] [Related]  

  • 18. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
    Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of troglitazone in type 2 diabetes mellitus.
    Rusk MH
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
    [No Abstract]   [Full Text] [Related]  

  • 20. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
    Murase Y; Wakasugi T; Yagi K; Mabuchi H
    Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.